The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area
Cole, M.J., Quinten, C., Jacobsson, S., Day, M., Amato-Gauci, A.J., Woodford, N., Spiteri, G., Unemo, M., Stary, A., Haller, M., Verbrugge, R., Crucitti, T., Soteriou, S., Pieridou, D., Cowan, S., Hoffmann, S., Epstein, J., Viktorova, J., Ndeikoundam, N., Goubard, A., Kohl, P., Buder, S., Bremer, V., Tzelepi, E., Konte, V., Balla, E., Dudás, M., Sigmundsdóttir, G., Hauksdóttir, G.S., Igoe, D., Crowley, B., Suligoi, B., Stefanelli, P., Pakarna, G., Mavcutko, V., Barbara, C., Melillo, J.M., Van Dam, A., Van Benthem, B., Linde, I., Kløvstad, H., Bergheim, T., Majewski, S., Mlynarczyk-Bonikowska, B., Azevedo, J., Borrego, M.J., Pavlik, P., Truska, P., Klavs, I., Jeverica, S., Vazquez, J., Diez, M., Velicko, I., Unemo, M., Hughes, G., Eastick, K.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in Neisseria gonorrhoeae in 24 European countries: an ecological analysis.
Kenyon, C., Buyze, J., Spiteri, G., Cole, M.J., Unemo, M.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Event-based surveillance for emerging infectious diseases in the EU/EFTA
Santos-O'Connor, F., Mantero, J., Vasconcelos, P., Mollet, T., Ciotti, M., Coulombier, D.